Publication

Longer follow-up reaffirms subcutaneous epcoritamab induces deep and durable complete remissions in patients with relapsed/refractory large b-cell lymphoma: updated results from the pivotal EPCORE NHL-1 trial

Karimi, Y
; 
Ghesquieres, H
; 
Jurczak, W
; 
Cheah, CY
; 
Clausen, MR
; 
Lugtenburg, P
; 
Cunningham, D
; 
Do, YR
; 
Lewis, DJ
; 
Gasiorowski, R
... show 10 more
Citations
Altmetric:
Abstract
Authors
Karimi, Y
Ghesquieres, H
Jurczak, W
Cheah, CY
Clausen, MR
Lugtenburg, P
Cunningham, D
Do, YR
Lewis, DJ
Gasiorowski, R
Kim, TM
van der Poel, M
Poon, ML
Feldman, T
Linton, Kim M
Sureda, A
Hutchings, M
Stirner, MC
Liu, Y
Kilavuz, N
Sacchi, M
Thieblemont, C
Affiliation
The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, United Kingdom.
Description
Date
2023
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Karimi Y, Ghesquieres H, Jurczak W, Cheah CY, Clausen MR, Lugtenburg P, et al. Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023 SEP;23:S438-S. PubMed PMID: WOS:001062479600463. English.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/626739
Embedded videos